Advancing Pediatric Oncology: Precision Diagnostics & Therapies
*Corresponding Author: Victor A. Santos, Rio de Janeiro Health Institute, Brazil, Email: vsantos@riodejaneriohealth.brReceived Date: Sep 01, 2025 / Accepted Date: Sep 29, 2025 / Published Date: Sep 29, 2025
Citation: Santos VA (2025) Advancing Pediatric Oncology: Precision Diagnostics & Therapies. jcd 09: 316.DOI: 10.4172/2476-2253.1000316
Copyright: © 2025 Victor A. Santos This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricteduse, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Pediatric oncology is rapidly evolving with significant advancements across diagnostics and treatment. Genomic profiling [1],
liquid biopsy [2], and precision diagnostics in neuroblastoma [3] and brain tumors [4] are enabling targeted therapies. Proteomic
approaches [5] and epigenetic biomarkers [10] are identifying novel indicators for sarcomas and other cancers. \textit{Minimal
Residual Disease} (MRD) monitoring [6], alongside traditional immunohistochemistry [9], refines treatment efficacy. Precision
oncology [7], bolstered by Artificial Intelligence (AI) [8], is personalizing care, promising improved outcomes by integrating diverse
molecular insights into clinical practice for childhood cancers.
